Promoter inhibition by DNA methylation: a reversible signal☆
References (18)
- et al.
A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus
Cell
(1985) - et al.
N6-methyldeoxyadenosine residues at specific sites decrease the activity of the E1A promoter of adenovirus type 12 DNA
J. Mol. Biol.
(1986) - et al.
Reactivation of the methylation-inhibited late E2A promoter of adenovirus type 2 DNA by a strong enhancer of human cytomegalovirus
Virology
(1988) - et al.
Reactivation of the methylation-inactivated late E2A promoter of adenovirus type 2 by E1A (13S) functions
J. Mol. Biol.
(1988) - et al.
Inactivation by sequence-specific methylations of adenovirus promoters in a cell free transcription system
J. Virol.
(1988) DNA methylation — a regulatory signal in eukaryotic gene expression
J. Gen. Virol.
(1981)DNA methylation and gene activity
Annu. Rev. Biochem.
(1983)- et al.
Site-specific promoter methylations and gene inactivation
- et al.
Eukaryotic gene inactivation by sequence-specific promoter methylation and the release of the transcription block
Cited by (17)
Epigenetic mechanisms regulate the prostaglandin e receptor 2 in breast cancer
2012, Journal of Steroid Biochemistry and Molecular BiologyCitation Excerpt :DNA methylation is one essential component of epigenetics, exerting direct control over gene expression through the organisation of local chromatin structure for the allowance or blockage of access by transcriptional machinery [15]. Importantly, epigenetic processes such as DNA methylation are reversible with drug treatments, making these compounds a possible therapeutic agent [16]. It has previously been demonstrated that CYP19A1 transcription can be epigenetically regulated.
Improving the safety of embryo technologies: Possible role of genomic imprinting
2000, TheriogenologyDNA methylation: eukaryotic defense against the transcription of foreign genes?
1992, Microbial PathogenesisInitial characterization of the four promoters of the human insulin-like growth factor II gene
1991, Molecular and Cellular Endocrinology
- ☆
Presented at the New England Biolabs Workshop on Biological DNA Modification, Gloucester, MA (U.S.A.) 20–23 May 1988.
- ∗∗
Present address: INSERM-CNRS, Centre d'Immunologie,70 Route L. Lachamp, Case 906, Marseille 13288 (France) Tel. (91)269477; (U.M.) Department of Molecular Biology, Lewis Thomas Laboratory, Princeton University, Princeton, NJ 08544 (U.S.A.) Tel.(609)452-5993; (U.L.) Department of Microbiology and Immunology, University of California School of Medicine, San Francisco, CA 94143 (U.S.A.)Tel. (415)476-2824.